Guggenheim Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target upped by research analysts at Guggenheim from $1,030.00 to $1,100.00 in a research report issued on Monday, Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim‘s price objective would indicate a potential upside of 16.78% from the stock’s previous close.

A number of other brokerages also recently weighed in on REGN. Bank of America raised their target price on Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Sanford C. Bernstein upped their price target on shares of Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the company a “market perform” rating in a research note on Friday, August 14th. BMO Capital Markets upped their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Finally, Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $880.45.

Regeneron Pharmaceuticals Trading Up 1.5%

NASDAQ:REGN opened at $941.96 on Monday. The firm has a market cap of $96.98 billion, a P/E ratio of 20.87, a P/E/G ratio of 1.57 and a beta of 0.10. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.66 and a current ratio of 4.06. The firm’s fifty day moving average is $793.30 and its 200-day moving average is $738.05. Regeneron Pharmaceuticals has a 52 week low of $591.52 and a 52 week high of $935.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. During the same quarter in the prior year, the company earned $11.83 earnings per share. The company’s quarterly revenue was up 36.3% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, insider Andrew J. Murphy sold 4,147 shares of the business’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider directly owned 47,833 shares in the company, valued at $36,960,559.10. The trade was a 7.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the transaction, the executive vice president owned 13,134 shares of the company’s stock, valued at approximately $11,163,900. The trade was a 8.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,093 shares of company stock valued at $6,506,845 over the last three months. Insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in REGN. Western Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $26,000. Armstrong Advisory Group Inc. lifted its position in Regeneron Pharmaceuticals by 466.7% in the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 28 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the second quarter worth $29,000. Trust Co. of Vermont bought a new position in Regeneron Pharmaceuticals during the second quarter valued at $29,000. Finally, Fiduciary Financial Advisors bought a new position in Regeneron Pharmaceuticals during the second quarter valued at $29,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong quarterly results: Regeneron reported $5.12 billion in revenue, up 36% year over year and above the $4.58 billion analyst consensus. Adjusted earnings of $20.07 per share also exceeded expectations of $16.51. Regeneron revenue jumps 36% on a bigger Sanofi profit share
• Positive Sentiment: Dupixent remains the primary growth engine: Global quarterly Dupixent sales rose 35% to approximately $6.5 billion, reinforcing the strength of Regeneron’s collaboration with Sanofi and supporting expectations for continued earnings growth. Regeneron: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Pipeline and commercial catalysts: Investors highlighted encouraging Libtayo data in high-risk skin cancer, an expanded BARDA supply agreement for Ebola treatment, and management’s comments about a deep development pipeline. Ongoing share repurchases may also support per-share results. Regeneron Earnings Call Highlights Explosive Growth, Deep Pipeline
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, or $3.76 annualized, payable December 3 to shareholders of record November 20. The approximately 0.4% yield is modest but signals continued shareholder returns.
• Neutral Sentiment: Citigroup has forecast further appreciation, while the stock’s breakout to a two-year and 52-week high reflects strong investor momentum. However, the recent rally raises questions about how much future growth is already reflected in the valuation. Regeneron Bolts Higher on Dupixent Dominance
• Negative Sentiment: At roughly $928 per share, Regeneron has risen substantially and may face profit-taking or valuation pressure if future results do not maintain the current pace of growth. Regeneron Stock Looks At A Discount To Earnings

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.